title: Rational pharmacotherapy (RPT) in goutology: Define the serum uric acid target & treat-to-target patient cohort and review on urate lowering therapy (ULT) applying synthetic drugs.
abstract: A gout revolution is at hand as can be seen from the number of publications and our recent increase in a better understanding of gout regarding imaging, regarding pathogenetic involvement of crystals, cells and cytokines, as well as regarding new pharmacotherapeutic options. We should now focus on rational pharmacotherapy to significantly improve gout care. With modern combinations of xanthine oxidase inhibition PLUS uricosuric all serum urate concentrations can be targeted. The pharmacotherapeutic literature of synthetic urate lowering treatment is reviewed and a plea is given for rational pharmacotherapy combining different modes of action aiming at the rheumatologically predefined optimal serum urate concentrations instead of a more reluctant approach to just lower a serum urate to any lower level with a fixed dose allopurinol.
authors.affiliation: RadboudUMC, Rheumatology, Nijmegen, The Netherlands. Electronic address: t.jansen@radboudumc.nl.
authors.forename: Tim L
authors.initials: TL
authors.lastname: Jansen
mesh_terms: D006073:Gout / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood*; D014528:Uricosuric Agents / Q000627:therapeutic use*
chemical_list: D014528:Uricosuric Agents; D014527:Uric Acid
keywords: Allopurinol; Benzbromarone; Combination therapy; Febuxostat; Probenecid; Rational pharmacotherapy; Ulodesine; Urate lowering therapy (ULT)